Research in upper gastrointestinal cancers makes a leap forward
In the last few years, study findings have changed clinical practice and offered new opportunities of care to many patients
Adjuvant immunotherapy reduces relapse risk in resected or ablated hepatocellular cancer
Data from the IMbrave050 study show benefits of atezolizumab plus bevacizumab in terms of disease recurrence, but long-term data are needed
First-line pembrolizumab combination significantly improves PFS in HER2-positive metastatic G/GEJ adenocarcinoma
Adding immunotherapy to standard of care shows benefit compared with placebo and is confirmed to be practice-changing for this patient population
Data are still insufficient to recommend immune checkpoint inhibitors in perioperative therapy for gastric/gastro-oesophageal junction cancers
The impact of immunotherapy on disease progression and survival remains uncertain, but biomarker selection may be the future